Key result
Baseline global longitudinal strain predicts chemotherapy-induced ventricular dysfunction in breast cancer patients.
Why the study?
Does baseline global longitudinal strain (GLS) predict the subsequent development of ventricular dysfunction secondary to cardiotoxic drugs in patients with breast cancer treated with anthracyclines?
Cohort (n=93)
Does baseline global longitudinal strain (GLS) predict the subsequent development of ventricular dysfunction secondary to cardiotoxic drugs in patients with breast cancer treated with anthracyclines?
Baseline global longitudinal strain (using a cut-off of 17.5%) can help identify breast cancer patients starting cardiotoxic therapy who are at higher risk of developing ventricular dysfunction and require closer echocardiographic monitoring.
Answers are grounded in this paper and cite their sources.
Baseline GLS may stratify cardiotoxicity risk in breast cancer; leaves open prospective validation before guiding monitoring.
Funding Acknowledgements Type of funding sources: None. Introduction The monitoring of the left ventricular ejection fraction (LVEF) is a common practice in patients with breast cancer undergoing chemotherapeutic treatment. Although indiscriminate follow-up is not very cost-effective, we don’t have enough data to determine which patients would benefit from it. Purpose To analyze if any baseline ventricular function echocardiographic parameter can help to identify the subsequent development of ventricular dysfunction secondary to cardiotoxic drugs (DV-CTOX). Methods Retrospective study of patients with breast cancer who have received treatment with anthracyclines with / without adjuvant treatment with immunotherapy and / or radiotherapy. We analyzed baseline and follow-up ventricular function parameters (LVEF estimated by 2D-3D automatic quantification and semi-automatic quantification of global longitudinal strain (GLS)). Results We included 93 patients (mean age 59 ± 11 years, 98.9% women). 67% received immunotherapy and 84% radiotherapy. Median follow-up was 6 months. 10 patients (11%) developed DV-CTOX. There were differences in baseline clinical characteristics between patients and those with no DV-CTOX. Regarding echocardiographic parameters we didn’t observe differences between both groups in basline 2D LVEF (65 ± 1% vs 62 ± 14%, p = 0.4), and 3D LVEF (60 ± 7% vs 57 ± 8%, p = 0.4), although the GLS was lower in patients who later developed DV CTOX (GLS 19 ± 3% vs 16 ± 3%, p = 0.03); At follow-up, patients who developed DV-CTOX had worse LVEF estimated by 2D-3D and maintained a worse GLS value (52 ± 7% vs 69 ± 8% p <0.001.49 ± 8% vs 61 ± 4%, p = 0.005 and 14 ± 3% vs 20 ± 4%, p = 0.04 respectively). We used the area under the curve for the use of baseline GLS as a diagnostic method for the early detection of DV-CTOX. It was 0.785 (CI 0.585-0.985 for a p value = 0.047). A baseline GLS cut-off point of 17.5% was determined with a sensitivity of 73% and a specificity of 80%. Conclusion The quantification of baseline GLS in patients with breast cancer who are going to start treatment with cardiotoxic drugs could help to discriminate which patients require a closer LVEF monitoring, improving efficiency in the Cardio-Onco-Hematology unit. A value greater than 17.5% in absolute terms of baseline GLS could be an optimal cut-off point that discriminates between patients who will develop DV-CTOX. Abstract Figure. Abstract Figure.
No takes yet. Share an insight, caveat, or question.
Martinez et al. (2022) conducted a cohort in Breast cancer undergoing anthracycline chemotherapy (n=93). Baseline global longitudinal strain (GLS) quantification vs. Patients who did not develop ventricular dysfunction vs. those who did was evaluated on Development of ventricular dysfunction secondary to cardiotoxic drugs (DV-CTOX) (AUC 0.785, 95% CI 0.585-0.985, p=0.047). Baseline global longitudinal strain predicted cardiotoxicity-induced ventricular dysfunction in breast cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: